In wet-granulated tablet production, Banxia Powder Veterinary Grade API is dry-blended at 10–30 wt% of the core tablet mass with microcrystalline cellulose and pregelatinized starch before addition of an aqueous binder. The mucilage-rich fraction of the powder releases sticky polysaccharides during wetting, which reduces the requirement for high-viscosity binder systems but narrows the acceptable granule-growth endpoint. On production-scale high-shear mixers with impeller tip speeds of 4–8 m/s, batch-to-batch moisture sorption from ambient air above 60% RH shifts wet mass consistency sufficiently to alter final tablet hardness by 10–20 N. Pre-drying of the API at 50–60 °C for 2–4 h is specified whenever warehouse relative humidity exceeds 60% RH. Aqueous binder is prepared using PVP K30 at 3–5 wt% solution, with granulation liquid addition time of 5–12 min. Granulation endpoint is controlled by loss-on-drying between 2.0% and 4.5%; dried granules are passed through a 1.0–1.5 mm screen and blended with croscarmellose sodium and magnesium stearate. Direct compression of the as-supplied powder is not recommended because rotary tablet press trials without forced feeding show fill-weight relative standard deviations above 8%. Compression on a rotary tablet press equipped with force feeders at 12–22 kN produces cores with target hardness 70–100 N and friability below 1.0% after 100 revolutions under USP <1216>. Tablet disintegration is evaluated in 0.1 M hydrochloric acid at 37 °C using Chinese Veterinary Pharmacopoeia 2020 Edition methodology. Compliance for oral veterinary tablets additionally covers microbial limits under USP <2021> and <2022>, residual solvents under USP <467>, and elemental impurities under ICH Q3D. Terminal finished product types include uncoated or film-coated tablets in 50 mg, 100 mg, and 500 mg dose strengths for companion animals, swine, and small ruminants.

When Banxia Powder Is Reconstituted for Parenteral Administration

Injectable solution development with Banxia Powder Veterinary Grade API is restricted to low-endotoxin, highly clarified extract grades because crude herb powder carries particulate and microbial load that cannot be removed by simple terminal filtration. The downstream process begins with dissolution of the dried extract in Water for Injection at 40–50 °C, followed by pH adjustment to 6.0–7.0 with 0.1 N sodium hydroxide or hydrochloric acid. For a 10 mL single-dose formulation, the initial addition ratio is in the range of 0.05–0.5 wt% of dried extract in the finished volume; published data for this specific configuration is limited, and feasibility is assessed by clarity, sub-visible particle count, and marker recovery after 14-day accelerated storage at 40 °C / 75% RH. Clarification uses depth filtration followed by two-stage membrane filtration through 0.45 μm and 0.22 μm PVDF cartridges under nitrogen pressure below 1.5 bar. Pre-filtration bioburden is controlled to ≤10 CFU/100 mL before the 0.22 μm membrane in accordance with EU GMP Annex 1 expectations. Filter compatibility is evaluated under USP <1663> and <1664> to avoid extractable/leachable contamination from sterilizing-grade filters. Filling into depyrogenated glass vials occurs in an ISO 7 / Grade C environment with ISO 5 / Grade A local protection. If terminal sterilization is not feasible, aseptic filtration and hold-time validation are mandatory. Sterility testing follows USP <71>, bacterial endotoxin limits are verified according to USP <85> with a limit derived from the maximum bolus dose, and particulate matter is controlled under USP <788>. Terminal product types are limited to 10 mL single-dose vials and 100 mL multi-dose vials for cattle or swine, with the multi-dose format requiring preservative efficacy testing according to USP <51>.

Capsule Fill Operations and Moisture Management

During capsule fill operations, Banxia Powder Veterinary Grade API is rarely used without dry granulation because the native powder exhibits cohesive flow and clumps under screw-driven dosing heads. Roller compaction at 8–15 kN/cm roller force and screen milling to 0.8–1.2 mm granules yields a fillable granulate with Carr index below 30. A typical granulate formula contains 40–70 wt% of the API with microcrystalline cellulose and sodium starch glycolate; this ratio is adjusted downward when capsule fill weight exceeds 600 mg to control disintegration time. The granulate is filled on tamping-pin capsule machines at speeds up to 120,000 capsules/h; integrated checkweighers reject units outside ±3% of target fill weight. Granule moisture is kept below 5.0% to avoid embrittlement or cross-linking of gelatin shells; use of HPMC capsules is preferred when shell moisture sensitivity is problematic. Disintegration must meet USP <2040>, weight variation follows USP <2091>, and aerobic microbial counts are controlled under USP <2021>. Terminal product types include Size 0–2 two-piece hard capsules in 250 mg, 400 mg, and 600 mg fill weights for companion animal and small ruminant oral dosing.

What Particle Size Range Prevents Segregation in Oral Granule Sachets?

To prevent segregation in oral granule sachets, Banxia Powder Veterinary Grade API is converted via fluid bed spray granulation into free-flowing granules with controlled bulk density. The addition ratio in a concentrated sachet product is 10–30 wt% of the granule formula, while a top-dress oral powder for mixing into feed or water typically contains 0.5–2.0 wt% in the finished dose. Segregation of the API from excipients is minimized when the granule median particle size D50 is held between 150 μm and 300 μm and the span [(D90−D10)/D50] is below 1.8. Fluid bed process parameters include inlet air 60–75 °C, product temperature 35–45 °C, and spray rate adjusted to maintain a final loss-on-drying below 3.0%. Bulk density after drying is maintained at 0.45–0.65 g/mL to match volumetric filler cups and reduce fill-weight drift. The dried granules are packaged in aluminum sachets with desiccant, with dosage-unit uniformity tested under USP <905>, moisture by USP <921>, and microbial limits under USP <61> and <62>. Terminal product types include 1 g, 5 g, and 20 g unit-of-use sachets for swine, poultry, and companion animal administration.

Feed-mill premix processing of Banxia Powder Veterinary Grade API is executed by step-down blending rather than direct addition to finished feed, because the low inclusion rate and high agglomeration tendency of the raw powder create unacceptable carry-over and mix variability in single-stage ribbon blenders. The API is first triturated with ground corn cob or rice hull carrier at ratios from 0.05 kg/tonne to 0.50 kg/tonne of finished feed, then blended in a twin-ribbon mixer for 10–15 min to achieve a coefficient of variation below 5%. Carrier particle size is maintained between 250 μm and 600 μm to match the settling velocity of the active powder and reduce post-mix segregation. If the premix is pelleted, the conditioner is operated at 70–85 °C for 20–40 s; post-pellet liquid application of heat-sensitive formulations is used when assay loss exceeds 5% during steam conditioning trials. Compliance under EU Directive 2002/32/EC controls undesirable substances such as aflatoxin B1, and mycotoxin testing follows Commission Regulation (EU) No 574/2011 where applicable. Terminal product types include 25 kg multiwall paper premix bags, 1 kg foil-lined pouches for on-farm top dressing, and pelleted or extruded complete feed for swine, poultry, and rabbits.

Drinking Water and Oral Solution Formulation Requires pH Control Rather Than Simple Dispersion

For drinking water medication, Banxia Powder Veterinary Grade API is dispersed in deionized water with a suspending and buffering system rather than presented as a plain solution, because insoluble herbaceous particles settle rapidly and mucilage components may undergo pH-dependent hydrolysis. A starting formulation includes 1.0–5.0 g/L of the API, xanthan gum at 0.2–0.5 wt%, sodium citrate/citric acid buffer to maintain pH 4.5–6.0, and potassium sorbate at 0.1–0.2 wt% as preservative. High-shear dispersion at 3,000–5,000 rpm for 10–20 min precedes passage through a 0.5 mm in-line strainer; settling volume after 1 h is maintained above 90% of initial volume. Use of water above 30 °C during dispersion is avoided because heated mucilage can increase viscosity and reduce strainer throughput. Diluted stock solutions are light-protected in amber HDPE or laminated bag-in-box systems and used within 24 h after dilution to avoid microbial proliferation. Compliance requires aerobic plate count and specified microorganism absence under USP <61> and <62>, while chemical stability of marker constituents is evaluated by HPLC under ICH Q2(R1) conditions. Terminal product types include 1 L and 5 L amber HDPE containers or bag-in-box systems for poultry and swine drinking water lines, and oral drench form for calves.